Cure8 research brief
Shortening infliximab infusion times and omitting routine premedication did not raise infusion reaction rates in this pediatric IBD study. That could lessen time burden for children and families and improve clinic efficiency.
Pediatric patients receiving infliximab, parents and caregivers, infusion nurses and IBD clinicians, and clinic managers planning infusion service workflows.
This retrospective study compared 346 infusions with routine dual premedication and longer infusion times to 737 infusions with no universal premedication and shorter infusions. Acute infusion reaction rates were low and similar between groups, and routine premedication did not clearly lower early or overall anti‑IFX antibody detection.
The authors report no additional safety signal from shorter post‑infusion observation periods. Practice changes like omitting routine premedication and shortening infusion durations may be reasonable to consider in pediatric IBD infusion services, but local protocols, individual patient history, and clinician judgment remain important.
This is a retrospective, single‑center study in a pediatric referral center; results may not generalize to all settings. Decisions about premedication and infusion duration should consider individual infusion reaction history and local monitoring capabilities.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study directly compares two rescue medications used when intravenous steroids fail in acute severe ulcerative colitis, reporting similar short-term remission and safety but a slower early response with tacrolimus —...
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...
